FDA Announcing Approves Leqembi, New Treatment To Improve Alzheimer’s Patients

Alzheimer’s Disease: Discover How Leqembi Can Help Improve Cognitive Function

A new year and crucial medical news from The US Food and Drug Administration (FDA), which approved Leqembi (lecanemab-irmb) as a breakthrough therapy for Alzheimer’s by Accelerated Approval pathway.

Alzheimer’s disease is a degenerative neurological disorder affecting millions worldwide. Although treatments are available to manage the symptoms, scientists have been searching for a more effective way to combat the disease.

Alzheimer’s Disease

Alzheimer’s disease is a devastating and incurable illness that has affected over 6.5 million Americans and continues to be a growing problem. It is a progressive disorder that slowly deteriorates memory, thinking skills, and even the ability to carry out simple daily tasks.

Despite decades of research, the causes of Alzheimer’s are still unknown, but scientists have identified changes in the brain that can lead to its development. These changes involve the accumulation of amyloid beta plaques and tau tangles or neurofibrillary tangles in the brain, leading to neuron loss and damage to their connections, ultimately interfering with…